Dr. Gloria González-Aseguinolaza, Vivet Therapeutics CSO & Head of the Gene Therapy Dept. at FIMA, a leading research center in the field of Gene Therapy located in Pamplona (Spain), will present results related to Vivet Therapeutics’s VTX-801 gene therapy program for Wilson’s disease: Preclinical validation of radioactive copper excretion as a translational tool for evaluating the pharmacodynamics of gene therapy for Wilson’s disease in a dose escalation study (#1956) during the AASLD / The Liver Meeting 2019 in Boston.
